Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I
Objective: Evaluate the efficacy of opicapone (OPC) in Parkinson's disease (PD) patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background:…Minimizing levodopa titration period for Parkinson’s disease (PD)
Objective: Develop an optimization algorithm that individualizes the pharmacokinetics-pharmacodynamics (PKPD) infusion models of levodopa, to improve the efficacy of dose titration and reduce the number…Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC
Objective: To evaluate the functional impact of LSVT LOUD and LSVT ARTIC on voice and communication in individuals with Parkinson's disease (PD) immediately post and…STN-DBS in Parkinson’s disease with early motor complications – A 10 year follow-up
Objective: To investigate long-term outcome of subthalamic stimulation (STN-DBS).in Parkinson's disease (PD) patients with early motor complications. Background: STN-DBS improves motor complications and quality of…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms
Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Creatine for patients with Parkinson’s disease: A meta-analysis
Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib, a tyrosine kinase inhibitor (TKI) was examined with the aim of showing its effect on safety comparing a lower dose of 150mg (N=6)…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.